Optimizing RNA yield using deep neural networks coupled to massively parallel screening

Messenger RNA (mRNA)-based therapeutics have emerged as a powerful platform for vaccines, protein replacement therapies, and cancer immunotherapy. A critical bottleneck in mRNA development is manufacturing large quantities of RNA economically, as measured by RNA yield emerging from an in vitro transcription (IVT) reaction. However, how promoter-adjacent DNA sequences influence RNA yield remains poorly characterized. Here, we present an integrated deep learning framework that leverages massively parallel next-generation sequencing (NGS) assays to measure RNA yield across large sequence spaces. A library of 10^5 randomized oligonucleotide sequences was designed to systematically explore sequence diversity within a defined structural context. DNA and RNA abundances were quantified in parallel using Illumina sequencing, enabling high-resolution measurement of sequence-to-yield relationships at scale. Sequences were one-hot encoded and used to train deep learning models, using a convolutional neural network architecture. The model achieved a Pearson correlation of 0.94 between predicted and experimentally measured RNA yield on a held-out test set, demonstrating strong generalization across diverse sequence contexts. Importantly, the trained model can be deployed in a production environment to score and rank novel RNA sequence designs by predicted IVT yield, enabling cost-effective, pre-experimental prioritization of the most manufacturable candidates. This framework establishes a scalable, data-driven approach to DNA and RNA sequence optimization, with broad applicability to vaccine antigen design, therapeutic protein delivery, and synthetic biology. By integrating high-throughput experimentation with advanced deep learning modeling, it significantly reduces screening costs and accelerates RNA engineering cycle times.